MARKET

VIR

VIR

Vir Biotechnology, Inc.
NASDAQ
8.82
+0.06
+0.63%
After Hours: 8.85 +0.03 +0.34% 19:34 08/07 EDT
OPEN
8.87
PREV CLOSE
8.77
HIGH
9.03
LOW
8.75
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
11.66
52 WEEK LOW
4.155
MARKET CAP
1.49B
P/E (TTM)
-4.7384
1D
5D
1M
3M
1Y
5Y
1D
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders
Simply Wall St · 1d ago
Vir Biotechnology (VIR) Could Be 58% Below Fair Value On Q2 Profit Turnaround
Simply Wall St · 3d ago
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
TipRanks · 3d ago
Vir Biotechnology price target lowered to $19 from $21 at Leerink
TipRanks · 3d ago
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
TipRanks · 3d ago
Vir Biotechnology (VIR) Gets a Buy from Barclays
TipRanks · 3d ago
*Vir Biotechnology 2Q Rev $238.9M >VIR
Dow Jones · 4d ago
Press Release: Vir Biotechnology Provides -3-
Dow Jones · 4d ago
More
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. It also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Its key product candidates include Elebsiran (VIR-2218); Tobevibart (VIR-3434); VIR-5818; VIR-5525, and VIR-5500. These molecules leverage the PRO-XTEN masking technology with TCEs targeting CD3 on T-cells and HER2, PSMA and EGFR, respectively, on tumor cells. Elebsiran is an investigational hepatitis B virus (HBV)-targeted small interfering RNA that reduces hepatitis B surface antigen (HBsAg). Tobevibart is an investigational neutralizing monoclonal antibody that has been engineered for immune engagement and targets a conserved region on the HBsAg.

Webull offers Vir Biotechnology Inc stock information, including NASDAQ: VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.